2019-11-06
Ark Biosciences Reports Successful Completion of Phase II Proof-of-Concept Clinical Trial of Ziresovir for Treatment of Infants Hospitalized with Respiratory Syncytial Virus (RSV) Infection
know more >
2018-11-01
Ark Biosciences Reports Significant Progress of Phase 2 Clinical Trial of Ziresovir for Treatment of Hospitalized Respiratory Syncytial Virus (RSV) Infected Patients
know more >
2018-08-22
Ark Biosciences to Present Efficacy Data on Novel Ziresovir at an International Conference
Ark to present efficacy data on its novel RSV F-protein inhibitor, Ziresovir (AK0529) at the 11th International RSV Symposium in Asheville, North Carolina, USA, 31st October – 4th November 2018...
know more >
2018-07-25
Ark Biosciences Licenses a Clinical Stage Drug for Treatment of Idiopathic Pulmonary Fibrosis
Ark announced a license agreement for a Roche's potential drug for idiopathic pulmonary fibrosis...
know more >
2018-08-13
Ark Biosciences and KOLs Published a Review Paper on Antiviral Drug Resistance Across Chronic and Acute Infections
Antiviral therapy can lead to drug resistance, but multiple factors determine the frequency of drug resistance mutations and the clinical consequences...
know more >